It is estimated that 70–80% of breast cancer patients with a BRCA1 or 2 mutation have a TNBC subtype, and that about 20% of TNBC have a BRCA1 or 2 mutation [10]. The gene discussed is BRCA1; the disease is breast carcinoma.